Summer 2011 - WuXi AppTec

Pharmaceutical
Services
Structural Biology
X-Ray Crystallography
High Throughput Screening
Medicinal Chemistry
Synthetic Chemistry
Discovery Biology
Pharmacology
ADME - DMPK
Process R&D
Formulation
Analytical R&D
GMP Manufacturing
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
Summer 2011
GLP Bioanalytical Services
Non-GLP and GLP Toxicology

Page 2
What’s New
Contents
Dr. Ge Li Honored with BayHelix Lifetime Achievement Award
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
WuXi AppTec Invests in Greater Radiolabeling Capabilities to Support Drug Research
U.S. Executives and Biotechnology Industry Organization visit China and WuXi Apptec
Seasoned Industry Veterans Join WuXi Apptec
New Bioanalytical Facility Based in United States Opens
Service Spotlight
Expertise and Resources: Building a Better Oncology Platform
WuXi AppTec’s GLP Bioanalytical Services Meeting Bioequivalent Demand
Pre-Clinical Research Facility
Perspectives
Q&A with Dr. Jerry Xu - US FDA 21st Century Challenge
Distinguished Guest Speakers Lecture at WuXi
Dr. Richard Soll speaks at the “Powering Global Innovation” BayBio Conference
Upcoming Events

Page 1
Dr. Ge Li Honored with BayHelix
Lifetime Achievement Award
On April 10th, 2011, Dr. Ge Li, WuXi AppTec
Chairman and Chief Executive Officer, received
BayHelix Lifetime Achievement Award at the
BayHelilx 8th Annual Conference in Shanghai,
China.
BayHelix is an organization of leaders of
Chinese heritage in the global life sciences
and healthcare community, aiming to shape
the growth of the life sciences and healthcare
industry around the Pacific Rim and beyond;
foster and create business opportunities; supply
and nurture the leaders for the community; and
network and share information and experience.
Dr. Li was honored with the BayHelix Lifetime
Achievement Award in recognition of his
outstanding contributions to the pharmaceutical
industry in both China and the world. In the
past ten years, Dr. Ge Li pioneered China’s
pharmaceutical R&D CRO industry. Under Dr.
Li’s leadership, WuXi AppTec industrialized
pharmaceutical R&D services, transformed the
pharmaceutical industry, and attracted global
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
pharmaceutical companies to shift their R&D
into China.
“I am honored to receive the BayHelix Lifetime
Achievement Award,” commented Dr. Ge Li.
“This is recognition of WuXi AppTec’s integrated
R&D service model. The vision of WuXi AppTec
is to establish an integrated drug R&D service
platform to help anyone, any company achieve
real results by leveraging WuXi AppTec’s
resources to discover and develop new drugs
to benefit patients. Even
though this is a lifetime
achievement award, I’m
not done yet. In next
ten years, we want to
build WuXi AppTec into a
technology and platform
company. With China’s
economic development,
more people will have
better quality of life and
demand better drugs. I
will work with all WuXi
AppTec employees with
passion to continue to
serve the future needs of
pharmaceutical industry.”

Page 2
WuXi AppTec
Invests in Greater
Radiolabeling
Capabilities to
Support Drug
Research
WuXi AppTec acquired radiosynthesis specialty
firm Chemdepo based in Camarillo, CA in
March 2011.
The specialty firm was established in 2007
with a focus on custom synthesis of carbon
14 radiolabeled compounds, and stable
isotope labeled compounds. The company’s
3,000 ft 2 laboratory is fully equipped and
licensed for handling volatile and basic labeled
compounds.
Expertise includes:
h 14 C labeled intermediates, organometallic
complex compounds, organosilicon,
boronic reagents
h Custom labeling heterocyclic compounds
h Asymmetric synthesis of amino acids
h Synthesis of organophosphate, pesticides,
nucleosides and nucleotides
h Moisture sensitive 14 C labeled compounds
The Chemdepo facility was an attractive
partnership for WuXi AppTec due the high
quality of readily available 14 C radiochemicals
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
Vacuum line operation
and the dedication of the custom
radiosynthesis team. Chemdepo leaders Guo-
Qiang Cao, PhD and Michael Chang provide
almost 50 years of combined experience in
radio and organic synthesis.
The goals and integrity of the team align
well with the WuXi AppTec commitment to
excellence offering guaranteed confidentiality,
fast delivery (~4 weeks), and high purity
(>98%) at competitive prices. The addition
of this capability will increase Wuxi AppTec’s
integrated program of discovery services,
preclinical testing and manufacturing
operations.
Liquid Scintillation Counter

Page 3
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
U.S. Executives and Biotechnology
Industry Organization visit China and
WuXi Apptec
“For the US, Europe and Japan pharma
industries struggling with an increasing need
for R&D productivity and efficiency, China
is an attractive resource. In addition, the
Chinese market for pharmaceuticals, already
the third-largest in the world, is expected
to increase by 23%.” (1) Eyeing this fastmoving,
attractive market, Biotechnology
Industry Organization (BIO) and BioWorld,
dedicated time to covering the challenges and
opportunities of doing business in China.
BIO’s president and CEO, Jim Greenwood,
led a delegation of members to China as
a prelude to their partnering conference
scheduled later this year. Jim and executives
from the U.S. Biotech industry spoke with Tom
Wall of BioWorld regarding the status of the
biotech industry in China today. WuXi AppTec,
as the leading CRO in China, made headlines
in this segment.
Jim Greenwood proclaimed “China increasing
is stockpiling bright scientists, many who were
educated or worked in the U.S. and have
returned. There is a deep bench of scientists
able to do some very good frontline research.”
1 “China’s booming pharma sector welcomes western investors” Michael Stones, in-Pharma Technologist.com, April 4, 2011.

Page 4
“Sea turtles (a pun meaning ‘returned from
overseas’) contribute to biotech innovation
in China,” Dr. Ge Li, President and CEO of
WuXi AppTec noted, “with their advanced
education in top U.S. schools and vast
experience acquired from working many years
in big pharma companies and top biotech
companies in the U.S., Europe and Japan.
Innovation and entrepreneurship have no
boundary,” he explained. “China’s biotech
industry is growing faster today because it
is still at its early stage. Strong government
support and great interest and commitment
from returnees have also propelled the fast
growth of China’s biotech industry.” (2)
Joshua Boger, founder of Vertex
Pharmaceuticals Inc. spoke with BioWorld
about his visit to the WuXi AppTec site when
selecting a partner for the manufacture of
their new hepatitis C drug Incivek (Telaprevir).
“Suppliers all over the world were vying for the
commercial manufacturing. Our criteria are
quality and speed. Can they deliver? There
was not a single corner cut, you can eat off
the floor.” Boger said of WuXi’s SynTheAll
Pharmaceuticals manufacturing site. (3)
Boger was equally impressed with WuXi’s
Suzhou toxicology site “It’s the package to get
an IND started. The facilities were the best I’ve
ever seen.”
The BIO delegation found the only things
holding back the promising biotech industry in
China would be a cultural lack of innovation
and an under-developed intellectual property
protection system.
Like many First-in-China steps taken by WuXi
AppTec, innovation and IP protection have
been ingrained into the cultural fabric of the
company. As the new complex and advanced
biology programs showcase the innovation and
return business from dozens of top companies
proves, WuXi AppTec is a trusted innovator in
the drug discovery space.
Contributors
2 “Return of the Sea Turtles Hastens Chinese Innovation” Tom Wall, BioWorld Today, June 10th , 2011
3 “U.S. Executives Dispel the Myths of Operating in China” Tom Wall, BioWorld Today, May 18th, 2011
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
Biotechnology Industry Organization
(BIO), created in 1993, is the world’s
largest biotechnology organization
whose aim is to foster innovation
through advocacy, business
development and communications.
BioWorld is a publication that covers
news in the pharmaceutical and
biotechnology industry and scientific
breakthroughs worldwide. The
BioWorld online web site has been
internationally recognized as the most
comprehensive resource for strategic
biotechnology news and information.

Page 5
Seasoned Industry Veterans Join
WuXi Apptec
Jane Lin
Vice President, Regulatory Affairs and Clinical
Development
Over 14 years’ experience in the
pharmaceutical industry. Formerly Medical
Director in Merck Sharp & Dohme and
Baxter responsible for regulatory affairs,
clinical research, medical affairs and
pharmacovigilance in mainland China
and Hong Kong. M.D. from Xi’an Jiaotong
University and M.P.H. from Shanghai
Jiaotong University.
Jason Wan, Ph.D. and MBA
Vice President, Pharmaceutical Science
Over 21 years’ experience in
formulation and drug delivery R&D,
formerly Sr. Fellow and Head of
Exploratory Formulation Development
for Schering Plough/Merck. Prior
employers include Pfizer, Alza /
JNJ, and Syntex / Roche. Ph.D
in Pharmaceutical Sciences from
University of Southern California and
MBA from University of Michigan.
Richard J. Early, Ph.D.,
DABT
Senior Director, Toxicology
Over 10 years of experience in
contract toxicology research, over
25 years of academic research
and teaching, board certified in
toxicology (DABT), Ph.D. in Animal
and Nutritional Sciences from the
University of Wisconsin-Madison.
Gonghua Pan
Vice President of Operation
Head of Program Management Office
Formerly Director and Head of
Asia Research operation at Pfizer,
with over 16 years’ drug discovery,
outsourcing management and
continuous improvement experiences
at Pharmacopeia and Pfizer. Ph.D.
from University of Wisconsin-Madison,
MBA from School of Management at
Yale University and B.S. from Peking
University.
Jerry Xu, Ph.D.
Vice President of GMP QA and
Regulatory Affairs
Over 20 years’ experience in the
pharmaceutical industry. Formerly
CMC reviewer at FDA, Director
of Process Development at
Pharmaceutics International, Senior
Manager of Global Technical Support
at Wyeth, founder of Shanghai
Fleecon Biomedical Inc. Ph.D. from
Northeastern University.
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
Neng Yang Shih, Ph.D.
Chairman of Discovery Program Review
Over 25 years’ experience in medicinal
chemistry and drug discovery.
Formerly Executive Director and Head
of Chemistry at Merck’s Cambridge
site. Ph.D. in Organic Chemistry from
the University of Illinois at Chicago
and post-doctoral fellow at Columbia
University and Harvard University.
Sue McPherson, ERT
Executive Director, Toxicology
Over 20 years’ experience within the
CRO industry, in Europe (Huntingdon
Life Sciences), Canada and Asia
(Charles River Laboratories).
Responsibilities ranged from Study
Director, Study Director trainer,
Manager of Toxicology group in
Shanghai and Program Manager. MSc
from the University of Hertfordshire.
March 2011 was accepted as a
European Registered Toxicologist.
Shuhua Han, Ph.D.
Senior Director, NPII
20 years of experience in
immunological research, Associate
Professor in Baylor College of
Medicine, Ph.D. from University
of London, postdoctoral fellow in
University of Maryland and Duke
University.

Page 6
New Bioanalytical Facility Based
in United States Opens
New Bioanalytical Facility
Opened in May 2011.
WuXi AppTec recently opened a Bioanalytical Facility
strategically located in Philadelphia, PA to provide
sample analysis for US based companies that have
extremely tight deadlines. The site will test both small
molecules and biologics in preclinical and clinical
samples in GLP conditions. The new facility follows
same quality system as China Bioanalytical operation,
which has been successfully inspected by US FDA
and obtained GLP accreditation from China SFDA and
OECD.
The facility was sited in order to offer fast turnaround
time; 1-2 days for locally based companies rather than
4-6 days when sending the sample to China.
“We pride ourselves on the speed at which our
logistics team can expedite delivery of samples, taking
advantage of the Green Channel for customs clearance
and the free trade zone. 95% of samples clear customs
within 24 hours, but in some very sensitive trials the
extra few days is worth more than the savings found
by using low cost locations” says Jinsong Xing, Vice
President of Bioanalytical Service.
WuXi understands the time-sensitive situation
encountered for certain therapeutics. WuXi
PharmaTech acquired AppTec back in 2007 to increase
the biologics and medical device reach of WuXi but
also to establish a North America presence because
sometimes clients require a testing site close to their
trial site. Having facilities in both the US and China
enables WuXi to provide tailor-made service to our
strategic partners.
Obviously, the bioanalytical asset will grow to serve
more clients and sample types such as large molecules
and drug product analysis.
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011

Page 7
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
Expertise and Resources: Building a
Better Oncology Platform
WuXi AppTec has been investing in people
and technology to bolster our biology and
pharmacology expertise across major
therapeutic areas. A dedicated and highly
qualified team of oncology experts has an
ambitious plan to bring our clients the most
up-to-date translational models for one of the
most genetically diverse diseases.
The WuXi strategy of bringing together a team
of top industry experts and providing resources
to pursue the most advanced technologies
is a resounding success. In the last one and
a half years, the team has developed and
validated an in vitro platform including cellbased
phenotypic and biomarker assays and
in vivo tumor models including > 70 cell line
xenograft models, orthotopic tumor models
with bioluminescent analysis, and patientderived
primary tumor models.
“We chose to expand the orthotopic models
because they represent the next phase in
cancer research,” said Chi-Chung Chan, Ph.D.
Gross and bioluminescent imaging of dissected
left (L) and right (R) brain lobes at the end of
experiments, showing no local metastasis. Arrows
indicate primary tumors.
Vice President of Biology, Head of Oncology.
“The subcutaneous xenografts have a place
when done properly and data are interpreted
appropriately, but the more sophisticated
approach of implanting the tumor in the target
organ eliminates one of the factors that prevent
the mouse model from being highly predictive
of a drug’s effectiveness in humans.”
WuXi is one of the few Chinese CROs that
invested in equipment and training for the
Xenogen IVIS imaging system to track the
progress of implanted tumor development.
A recent example of the combination
of orthotopic tumor growth models and
bioluminescent analysis is illustrated
by the U87-luc glioblastoma model. A
validation study with 8 mice over 32 days
provided significant evidence of the robust
procedures implemented by the team. Mice
micro-injected with cells in the caudate
nucleus were monitored with the Xenogen
instrument throughout the study. Post study
histological examination of the excised tumors
demonstrates the cellular heterogeneity of
the orthotopic xenografts match human tumor
samples.

Page 8
In addition to the technical skills in developing
orthotopic models, our collaboration with
research hospitals in Shanghai and Beijing
has enriched our portfolio with patient-derived
primary tumor samples.
Subcutaneous xenograft models have been
an industry standard for years, lung cancer
being the most successful. However, using
patient-derived tumor models for phenotypic
evaluation is an example of advanced use
of the subcutaneous xenograft model. Our
validation of a patient derived lung cancer
tumor in a mouse using paclitaxel, cisplatic and
gemcitabine as controls demonstrates effective
screening using this model (Fig 1).
Taking the patient-derived tumors one step
further for efficacy evaluation, WuXi AppTec
has successfully established orthotopic lung,
pancreas, esophagus, liver, and kidney tumor
models using patient samples. Validation using
standard-of-care agents including gemcitabine
show the implanted pancreatic tumor in an
orthotopic model behaves as expected for the
human tumor, retaining the original phenotype
(Fig 2).
Vehicle
5-FU
Gemcitabine
1 cm
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
Tracking Tumor Models
The Xenogen IVIS Lumina II imaging
system is in full operation with over
20 cell lines.
Fig.1 Lung Cancer Patient Tumor S.C. Xenografts in Nude
Mice - Tumor Volume
A tumor tissue bank with reliable, complete clinical information allows us to provide a translational
research link with robust animal models. Furthermore, gene expression profiling and genetic
analysis of patient derived tumor models provide critical information for model selection. The data
of efficacy in mouse studies and molecular characteristics of clinical samples bridge our research
from bench into clinic.
WuXi invests in the platform, skills and know-how to help our innovative clients advance
therapies to treat cancer more effectively.
Fig.2 Tumors from mouse model of patient-derived pancreatic cancer

Page 9
WuXi AppTec’s GLP
Bioanalytical Services Meeting
Bioequivalent Demand
Bioequivalence Studies- Uptick in
Need for Fast Efficient Bioanalytical
Studies to Support Generic Filings.
WuXi AppTec offers comprehensive
bioanalytical services for both innovator
and generic pharmaceutical companies.
Thousands of samples have been analyzed in
the past year to demonstrate bioequivalence
of generics often produced by the innovator of
the brand name drug.
In most cases an equivalent substance will
have the same active ingredient, dosage
form, route of administration, and be identical
in strength. This is all to ensure that two
products are bioequivalent - that is, they have
the same clinical and safety profile. Testing
for bioequivalence is the last step in showing
Therapeutic Equivalence to a reference listed
drug.
WuXi has developed and validated testing
methodologies for evaluating the plasma
drug concentration for a variety of systemic
drugs. High throughput sample analysis
using API 4000/5000/5500 and UPLC/Tomtec
instruments ensure fast turnaround times “We
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
are able to quickly emulate the methodology
for the reference substance at a level of
validation suitable for ANDA submission” says
Joe Wong, WuXi AppTec Senior Director
Bioanalytical Services. “We don’t charge for
the validation of an existing method keeping
down costs for our clients. In a field where
speed and regulatory compliance are essential
our customers rely on us because of our robust
process and internal audits; our Shanghai
Bioanalytical facility has passed multiple global
inspections; US FDA inspected in 2009 with no
483 observations and GLP-certified by OECD
and sFDA.”
Bioequivalence testing is usually assessed
by single dose in vivo studies in healthy
volunteers. The most challenging part of
rapidly testing human samples is often
delivering the samples from the clinic to the
lab. In the 10 years that WuXi AppTec has
been doing business for Western pharma, an
efficient system was established for importing
and exporting materials. We took this same
system and applied it to human plasma
samples removing any delay, allowing for
fast data analysis. Over 4,500 deliveries we
received without delay in 2010 alone.

Page 10
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
Pre-Clinical Research Facility
Supporting Global Filings with Cost Effective Solutions
WuXi regularly performs acute and repeat dose toxicology studies in both small and large animals.
Working closely with Multinational Pharmaceutical and Biotech companies, WuXi supports many
clients in North America, Europe and Asia in their drug development efforts for international
submission.
Our toxicology studies in both small and large animals as well as our laboratory services are
conducted in full compliance with international Good Laboratory Practice (GLP) regulations. In
addition, all protocols are designed to meet the regulatory requirements of the various countries in
which the products are to enter clinical trials or be marketed.
By focusing on quality, scientific expertise, flexibility, and responsiveness, WuXi collaborates with
its sponsors to provide cost effective solutions with meaningful and compliant results.
Overview of Services
● General Toxicology
● Genetic Toxicology
● Safety Pharmacology
● Immunology
● Analytical Chemistry
● Bioanalysis
● Toxicokinetics and pharmacokinetics
As the only AAALAC-accredited CRO in
China to receive GLP certification from both
OECD and SFDA (State Food and Drug
Administration), WuXi helps our partners
accelerate their timelines at a significant
cost advantage.
For general inquiries please contact us at
CS@wuxiapptec.com

Page 11
The FDA Strategic Priorities 2011-
2015 guidance document was
released last month. We asked Dr.
Jerry Xu to answer a few questions
regarding the impact of these
priorities for WuXi AppTec and our
clients.
Jerry Xu, Ph.D. is the Vice
President of GMP QA and US
Regulatory Affairs. He has over
20 years of experience in the
US pharmaceutical industry. His
former roles include CMC reviewer
at FDA, Director of Process Development
at Pharmaceutics International, and Senior
Manager of Global Technical Support at
Wyeth.
Dr. Xu is responsible for managing WuXi
AppTec’s quality assurance for GMP
operations. His oversight includes designing
and setting up quality systems for the
dedicated drug substance and drug product
stability testing lab for Bristol-Myers Squibb.
Q: The guidance document laid out five ‘crosscutting’
priorities areas for the US FDA over the
next five years. Which of these areas do you
feel will have the most impact on WuXi and the
pharmaceutical drug development space?
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
Q&A with Dr. Jerry Xu - US FDA 21st
Century Challenge
US FDA Cooperation
WuXi AppTec’s 15,750 sq. ft. facility in
Shanghai was audited by the US FDA
in 2009 (with no 483 observations).
A: The FDA commissioner
selected five areas to serve
as strategic priorities over
the next five years. These
include efforts to: 1) Advance
regulatory science and
innovation; 2) Strengthen
the safety and integrity of
the global supply chain;
3-4) Strengthen efforts to
meet needs of public health
and special populations;
and 5) Advance medical
countermeasures and
emergency preparedness.
Among these, I feel that the first and second
will have the most impact on us. The second
“Strengthen the Safety and Integrity of the
Global Supply Chain”, in particular, will have
impact on global pharmaceutical companies,
such as WuXi in China. We expect the
FDA will strengthen its compliance and
enforcement activities aboard. The Agency
plans to implement new programs and tools
to sharpen the effectiveness of its compliance
and enforcement system.
WuXI AppTec is in a unique position. We
compete not only in pricing but also in quality
services and reliability. WuXi has stellar track
record with over 100 successful customer
audits, in both the drug substance and drug
product arenas.As a leading CRO in Asia,
we have no one to follow but ourselves.
Besides building a first class quality system
that serves our global pharmaceutical clients,
we believe in continuous self-improvement.
Our goal is to improve our service, each
time better than the last. This company
culture differentiates WuXi from many of our

Page 12
competitors. It provides a solid foundation for a
good quality system. The FDA’s new Strategic
Priorities will help further WuXi’s position to
serve those who seek quality services in a
CRO .
Q: Asia has been the subject of some specific
issues regarding supply chain integrity
(contaminated Heparin, melamine-tainted pet
foods) for example. How does WuXi ensure
the integrity of the intermediates sourced
for the manufacture of API and clinical trial
materials?
A: WuXi has a rigorous supply chain
management process in place. We audit
and qualify our suppliers before sourcing
raw materials and intermediates. We also
have in-coming material QC process in place
before releasing materials for manufacturing.
We have an impeccable track-record; our
qualification process has never allowed any
material discrepancy to pass from our audit to
our client’s product.
Q: The guidance document states the FDA
must require more and better information
about supply chains involving more strategic
and consistent coordination among foreign
counterparts. Does WuXi work with the China
State Food and Drug Administration (SFDA)?
A: Yes, WuXi AppTec’s facilities in Suzhou,
Tianjin, and Shanghai have all been inspected
by the SFDA. We work extensively with the
SFDA with the mutual goal of ensuring the
safety of the local Chinese population. We are
in support of developing a global standard.
We also work with regulatory agencies in
Europe; in 2009 our drug product GMP facility
was certified by EMEA. Coordinating with
agencies around the world enables our service
to support and ensure safety for clients with
global markets.
My Overall Comment Summary:
As a leading CRO, our goal is to build a quality
system that is in line with FDA’s 21 st century
initiatives, a system that is both scientifically
justified and effective. We continue to improve
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
our quality system through training, through
internal audits, and by working closely with our
US clients to leverage each other’s expertise
on quality. In the continuous process of
building a first class quality system in China,
we will help strengthen the safety and integrity
of our client’s global supply chain outsourcing.
We are confident of our quality services. We
look forward to working closely with the FDA
in its future inspections of our GMP facilities.

Page 13
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
Distinguished Guest Speakers
Lecture at WuXi
May 19
Dr. Kun-Liang Guan
UC San Diego
Topic: The mTOR and Hippo
April 18,
Professor Sunney Xie
Harvard University
Topic: Hold Life Processes
up to the Light: Imaging and
Sequencing Single Molecules in
Singe Cells
April 21,
Dr. Junying Yuan,
Harvard Medical School
Topic: A Quest to Understand
the Mechanism of
Neurodegeneration
March 4,
Dr.Jos Brands
Merck
Topic: The Power of
Crystallization-Induced
Asymmetric Transformation
in Efficient Synthesis for NK1
Receptor Antagonist Aprepitant
May 20,
Dr. Robert E. Zelle
Concert Pharmaceuticals Inc.,
Topic: Serendipity and Drug
Discoveries—When Opportunity
Knocks, Will You Be There?
March 6,
Dr. Daniel Long
Theravance
Topic: A Multivalent Approach
to Drug Discovery for Novel
Antibiotics: Clinical Compound
TD-1792
March 21
Dr. Milana Maletic
Merck
Topic: A Medication for the
Fast Food Nation: Bicyclo
[2.2.2] octyltriazole Inhibitors
of 11beta-HSD1 For the
Treatment of Metabolic
Syndrome
Signaling Pathways in Cell
Growth, Organ Size, and
Tumorigenesis
March 16,
Professor Nan-Sheng Li
University of Chicago
Topic: Total Synthesis of
Enantiomeric Pureβ-D-Mannosyl
Phosphomy—coketide (C32—
MPM): A Natural Product from
Mycobacterium Tuberculosis32
April 13,
Dr. Colin D. Funk
Queen’s University
Topic: Lipoxygenases and
Leukotrienes in Health and
Disease
April 6,
Dr. Yu-Hui Rogers
The J. Craig Venter Institute
Topic: JCVI Research
Overview & Application of the
Next Generation Sequencing
Technologies at JCVI

Page 14
Dr. Richard Soll speaks at the “Powering
Global Innovation” BayBio Conference
Panelists and Moderator for discussion on China
innovation, R&D and clinical trials
BayBio, a life science association in California
USA, invited WuXi AppTec’s Richard Soll to
be a panelist at the plenary session “Emerging
Markets Strategies for R&D Success.”
The breakfast meeting was attended by over
400 industry members.
The panel was moderated by Gail Maderis and
included a diverse base of experts including:
Richard Soll, PhD,
Senior Vice President, Integrated Services, WuXi
AppTec
Gail Maderis,
President and CEO, BayBio
Sofie Qiao, PhD
President, CEO and Co-Founder, LINQ
Pharmaceuticals
James Sullivan, PhD
Vice President, Pharmaceuticals Discovery, Abbott
Gene Williams
Executive Chairman, Translational Medicine India
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
WXpress | Summer 2011
Breakfast Hall at BayBio Emerging Markets
Plenary Session
Upcoming Event
SFC, New York, NY USA, - July 20-22,
2011
ChemOutsourcing, Long Branch, NJ,
USA, - September 12-15
American College or Toxicology,
Phoenix, AZ USA November 6-9, 2011
CHPI, Frankfurt, Germany, - October
25-27, 2011
Please click the event above for the detailed
information.

Learn more at: www.wuxiapptec.com
Subscribe: WXPRESS@WuXiAppTec.com
Contact Us
Hui Cai, PhD, MBA
Vice President, Business Development
Phone: +1 858 361 8838 US
Phone: +86 138 1732 0515 China
Email: hui_cai@wuxiapptec.com
Naruhito Masai, PhD
Vice President, Business Development
for Japan and Specified Region
Phone: +86 21 5046 3725
Phone: +86 137 6173 3955
Email: masai@wuxiapptec.com
customer_service@wuxiapptec.com
info@wuxiapptec.com
Bill Farley
Vice President, Key Accounts
Phone: +1 651-398-4027 US
Email: bill.farley@wuxiapptec.com
Shanghai · Suzhou · Tianjin · Philadelphia · St. Paul · Atlanta
Pharmaceutical
Services
Summer 2011
Structural Biology
X-Ray Crystallography
High Throughput Screening
Medicinal Chemistry
Synthetic Chemistry
Discovery Biology
Pharmacology
ADME - DMPK
Process R&D
Formulation
Analytical R&D
GMP Manufacturing
GLP Bioanalytical Services
Non-GLP and GLP Toxicology
Lulu Tang
Assistant Director, Customer Service
Phone: +86 21 5046 2477
Phone: +86 186 0218 4268
Email: tang_lulu@wuxiapptec.com